Pfizer and Innovent Strike $10.5B Oncology Collaboration

The Chinese biotech pockets $650M upfront and could reel in nearly $9.85B in milestones across a deal spanning ADCs, multispecifics and co-commercialization rights in the U.S., EU and U.K.

Pfizer is the latest Big Pharma giant to plant a flag in China’s increasingly fertile oncology landscape, unveiling a sweeping 12-asset collaboration with Innovent Biologics that could be worth more than $10.5 billion if all milestones are met.

Announced Thursday, the tie-up gives Innovent $650 million upfront and the chance to claim up to $9.85 billion in development, regulatory and commercial milestones, plus tiered, potentially double-digit royalties on net sales of each licensed product. For Pfizer, it’s a hefty bet on a partner that has rapidly become one of the most coveted dance partners for Western drugmakers chasing next-generation cancer assets.

The pact is unusually broad. It bundles eight early-stage programs originating inside Innovent’s labs with four discovery-stage candidates proposed by Pfizer, including antibody-drug conjugates (ADCs) built around novel payloads and multi-specific antibodies engineered with differentiated immune-engaging features. In other words, Pfizer isn’t just licensing finished science; it’s effectively renting Innovent’s discovery engine to crank out new molecules to its specifications.

“Combining Innovent’s discovery and early clinical development with Pfizer’s global research and development and commercialization capabilities will not only strengthen our pipeline, but accelerate the delivery of breakthroughs that can redefine standards of care,” Pfizer Chief Oncology Officer Jeff Legos said in a statement.

How the deal is carved up

The structure is a hybrid that gives both sides flexibility and reflects the new reality that Chinese biotechs are no longer content to hand over global rights for a one-time check.

Four programs: Pfizer takes an exclusive global license and shoulders all development costs.
Four programs: Pfizer gets exclusive ex-China rights and runs the “majority” of development, while Innovent retains Greater China.
Four programs: A true co-development, co-commercialization play. The companies will split global development costs, share profits in the U.S., the EU, and the U.K., and allow Innovent to retain Greater China.

Across all 12 assets, Innovent will steer the candidates through Phase 1 before handing the keys to Pfizer for global late-stage work. That hand-off model, China-discovered, China-tested early, then globalized, has quietly become the template for a wave of cross-Pacific oncology deals.

Innovent’s hot streak

For Innovent, the Pfizer agreement caps a remarkable 18-month run that has transformed the Suzhou-based company from a domestic PD-1 player into one of the world’s most prolific dealmakers in oncology.

It comes less than four months after Innovent signed an $8 billion-plus pact with Eli Lilly to advance a clutch of oncology and immunology assets through Phase 2 in China. Stack the two deals together, and Innovent has lined up nearly $19 billion in potential biobucks since the start of the year, a number that would have been unthinkable for a Chinese biotech even three years ago.

Hui Zhou, chief R&D officer of Innovent’s oncology pipeline, framed Thursday’s announcement as a force multiplier rather than a handover. “By leveraging both companies’ complementary resources, we can develop our early-stage oncology pipeline with greater speed and impact to help bring innovative therapies to patients more efficiently worldwide,” she said.

Why Pfizer, why now

For Pfizer, the deal slots neatly into CEO Albert Bourla’s pledge to rebuild oncology into the company’s growth engine following the 2023 Seagen acquisition. ADCs and multispecifics, the two modality buckets at the heart of the Innovent collaboration, are precisely the areas where Pfizer’s competitors, including Merck, AstraZeneca, BMS and Roche, have been most aggressive in inking China-sourced licensing deals.

By pulling 12 shots on goal into a single agreement, Pfizer gets diversification, optionality and — critically, the ability to swap in Innovent’s discovery muscle on programs Pfizer’s own scientists conceived. If even a handful of these candidates clear Phase 1, the milestone meter will start ticking fast.

What remains to be seen is whether the deal can survive the geopolitical static now hanging over U.S.–China biopharma transactions. With the BIOSECURE Act still hovering over Sino-American deal flow and tariff rhetoric back in headlines, every transatlantic and trans-Pacific pact is now graded on regulatory durability as much as scientific merit.

For now, though, Innovent has another whale on the hook, and Pfizer has just placed one of the largest single bets of the year on the bench strength of Chinese drug discovery.